A multicenter study of anaplastic oligodendroglioma: the Korean Radiation Oncology Group Study 13-12.
Although some existing evidence supports the addition of chemotherapy (CT) to radiation therapy (RT) for anaplastic oligodendroglioma treatment, controversy about both the criteria for suitable candidates and the optimal treatment schedule remains. We reviewed data from 376 newly diagnosed anaplastic oliogodendroglial tumor patients from nine Korean institutes were reviewed from 2000 to 2010. Total tumor removal was performed in 146 patients. More than 85% of the entire patients received postoperative RT, and 59% received CT. Approximately 50% (n = 189) received CT in addition to RT and 9% (n = 32) received CT only. A multivariate analysis revealed that younger age, frontal lobe location of the tumor, gross total removal, 1p/19q codeletion, and initial RT were associated with longer progression-free and overall survival rates. No difference was observed in outcomes from the treatment that included either temozolomide or PCV (procarbazine, lomustine, and vincristine) in addition to RT regardless of the 1p/19q deletion status. A clear improvement in progression-free and overall survival was observed for RT and combined CT/RT in compared with CT only. Postoperative RT appears to improve survival for entire group thus total removal and 1p/19q codeletion may not be sufficient criteria to omit RT as a treatment option. These results suggest that RT should continue to be offered as the standard treatment option for patients with anaplastic oligodendroglial tumors.
Department of Radiation Oncology, Dongnam Institute of Radiological & Medical Sciences, Busan, Korea.
Hyun-Cheol
HC
Kang
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.
Tosol
T
Yu
Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Do Hoon
DH
Lim
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.
Il Han
IH
Kim
Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Korea.
Woong-Ki
WK
Chung
Department of Radiation Oncology, Yonsei Cancer Center, College of Medicine, Yonsei University, Seoul, Korea.
Chang-Ok
CO
Suh
Department of Radiation Oncology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Byung Ock
BO
Choi
Proton Therapy Center, Research Institute Hospital, National Cancer Center, Goyang, Korea.
Kwan Ho
KH
Cho
Department of Radiation Oncology, Gangnam Severance Cancer Hospital, Seoul, Korea.
Jae Ho
JH
Cho
Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea.
Jin Hee
JH
Kim
Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Do-Hyun
DH
Nam
Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea.
Chul-Kee
CK
Park
Department of Neurosurgery, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Yong-Kil
YK
Hong
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea. inah228@snu.ac.kr.|Department of Radiation Oncology, Seoul National University Bundang Hospital, 166 Gumiro Seongnamsi Kyeonggido, Seoul, 463-707, Korea. inah228@snu.ac.kr.
In Ah
IA
Kim
D000328:Adult; D000367:Age Factors; D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009837:Oligodendroglioma / Q000188:drug therapy* / Q000532:radiotherapy*; D016016:Proportional Hazards Models; D012372:ROC Curve; D011878:Radiotherapy / Q000379:methods*; D056910:Republic of Korea; D012189:Retrospective Studies; D016896:Treatment Outcome
D000970:Antineoplastic Agents
Oligoastrocytoma; Oligodendroglioma; PCV; Radiotherapy; Temozolomide